Idea for new board game.... Dying Drug Dynasties

[Guest guest]

Or perhaps... Corporate Corruption???

Thanks to Ken for all his hard work in compiling this information into one

easy, accessible place

http://www.psychsearch.net/lawsuits.html

Atypical Antipsychotics

Abilify, Geodon, Risperdal, Seroquel, Zyprexa

The TMAP Drugs (Texas Medication Algorithm Project)

TMAP and TeenScreen (video here, petition here)

Endorsed by the New " Freedom " Commission on Mental Health

Medicaid Okay to Pay? See here

Click link for Package Inserts:

Abilify - Bristol-Myers Squibb Company

Geodon - Pfizer

Risperdal - Janssen, a unit of &

Seroquel - AstraZeneca

Zyprexa - Eli Lilly

Click links for the references on lawsuits or subpoenas:

Unspecified States

Lilly has received civil investigative demands or subpoenas from the

attorneys general of a number of states. Most of these requests are now part

of a multistate investigative effort being coordinated by an executive

committee of attorneys general. Lilly says they are aware of 26 states

participating in this joint effort and they anticipate that additional

states will join the investigation. These attorneys general are seeking a

broad range of Zyprexa documents, including documents relating to sales,

marketing and promotional practices, and remuneration of health care

providers. SEC filing

Alaska

State of Alaska v. Lilly

Civil action for the damages and penalties arising from the marketing and

sale of the prescription drug Zyprexa Article Complaint Description of Claim

California

& 's Janssen unit received a subpoena from the California

attorney general's office over sales and marketing of Risperdal. The

subpoena asked for documents on " sales and marketing and side effects " of

the drug, as well as on " interactions with state officials " in Medicaid.

Article

In September 2006, Lilly received a subpoena from the California Attorney

General's office seeking production of documents related to their efforts to

obtain and maintain Zyprexa's status on California's formulary, marketing

and promotional practices with respect to Zyprexa, and remuneration of

health care providers. SEC Filing

Eli Lilly & Co., AstraZeneca PLC and Bristol-Myers Squibb Co., revealed that

they received subpoenas from California's Attorney General's office to

reveal information about their anti-psychotic prescription drugs. The

subpoena requests marketing practices and status on California's insurance

list of " preferred drugs. (Zyprexa, Seroquel, Abilify) Article

A Pfizer spokesman confirmed that the company received a subpoena Sept. 8,

2006 from the California attorney general's office concerning Geodon. The

company is " cooperating fully, " said the spokesman, who declined to

elaborate. Article

Florida

In June 2005, Lilly received a subpoena from the office of the Attorney

General, Medicaid Fraud Control Unit, of the State of Florida, seeking

production of documents relating to sales of Zyprexa and their marketing and

promotional practices with respect to Zyprexa. SEC Filing

Illinois

The Illinois attorney general's office demanded that Eli Lilly hand over

documents concerning the marketing of Zyprexa Article

Louisiana

State of Louisiana v. Janssen

A multimillion dollar civil lawsuit against Janssen Pharmaceutical alleges

unfair business practices and violations of consumer protection laws. The

lawsuit seeks damages for increased medical costs due to side effects

suffered and for increased Medicaid expenses due to misleading sales

pitches. The suit was filed in connection with the production and marketing

of the drug Risperdal.Article

State of Louisiana v. Eli Lilly, Brie Lablanc, Parikh and Gerald

Cahee, (Sales Reps for Lilly in Louisiana)

Upon information and belief, despite the fact that Zyprexa has not been

tested or approved by the Food and Drug Administration (FDA) for pediatric

use, Eli Lilly marketed Zyprexa, a potent anti-psychotic drug, for use with

children. As a result thereof, many children residing in the State of

Louisiana have suffered from Zyprexa related injuries and illnesses such as

diabetes, pancreatitis and seizures. Article Complaint

Mississippi

State of Mississippi v. Lilly

Mississippi became the fifth state to sue the Indianapolis drug maker over

its antipsychotic Zyprexa. Mississippi's attorney general, Jim Hood, charged

that Lilly promoted Zyprexa for unapproved uses, including for children. The

lawsuit by Hood seeks repayment from Lilly for more than $100 million that

the state's Medicaid program for the poor has paid for the drug, plus

reimbursement for diabetes-related injuries the drug caused some Medicaid

users. Article Complaint

Montana

State of Montana v. Lilly

Eli Lilly & Co. was sued by the state of Montana over claims the company

fraudulently marketed its antipsychotic drug Zyprexa for unapproved uses and

owes the state for prescription costs and harm to patients. Lilly allegedly

gave kickbacks to doctors and improperly promoted the drug to nursing homes

as a sedative, Montana Attorney General Mike McGrath said in a complaint

filed March 7, 2007 in state court in Helena. He claimed Lilly, the world's

biggest maker of psychiatric drugs, bought off a ``disgruntled'' sales

director to keep him from disclosing its marketing practices. Article

Complaint

New Mexico

State of New Mexico v. Lilly

Plaintiff seeks to recover the costs of Olanzapine (Zyprexa) induced

diabetes and diabetes related illnesses to the State of New Mexico.

Complaint

Ohio

Ohio has not sued directly but has attached claims - for $7.5 million so far

- to lawsuits involving 1,100 Ohio Medicaid beneficiaries. (Zyprexa) Article

Oregon

Oregon Attorney General Hardy Myers is investigating whether Eli Lilly

illegally promoted uses of Zyprexa that have not been approved by the U.S.

Food and Drug Administration. Article

Pennsylvania

Commonwealth of Pennsylvania v. Lilly, AstraZeneca, Janssen

Eli Lilly & Co., AstraZeneca Pharmaceuticals and & were sued

by Pennsylvania over claims they fraudulently marketed antipsychotic drugs

and owe the state for prescription costs and harm to patients. Lilly, based

in Indianapolis, hid the risks and exaggerated the benefits of its

antipsychotic medication Zyprexa while persuading doctors to prescribe it

for unapproved uses, the state said. London-based AstraZeneca PLC's U.S.

unit did the same for its drug Seroquel and & 's Janssen

Pharmaceutical unit for Risperdal, Pennsylvania claimed in a Feb. 26, 2007

complaint. Article Complaint

Texas

State of Texas and v. Janssen

The Texas attorney general says TMAP was just one part of an elaborate

marketing scheme to increase psychotropic drug sales. The Texas state

attorney general joined a whistleblower lawsuit this past December accusing

the pharmaceutical and consumer goods giant and inc. of

exaggerating the benefits and minimizing the known adverse effects

associated with its second-generation antipsychotic Risperdal (risperidone),

marketed by subsidiary Janssen L.P. Article Complaint

Vermont

Illinois attorney general Madigan has ratcheted up the pressure on

pharmaceutical giant Eli Lilly. Lawyers at the consumer protection division

of the Illinois attorney general's office last week demanded that company

officials hand over documents concerning the marketing of Zyprexa, Lilly's

blockbuster mental health drug. Their counterparts in the Vermont AG's

office have joined the action. Article

West Virginia

State of West Virginia v. Lilly

West Virginia Attorney General Darrell McGraw sued Eli Lilly in February,

2006 claiming that Zyprexa harmed West Virginia citizens. McGraw's suit

claimed Zyprexa sales benefited Eli Lilly at the expense of West Virginia's

Medicaid program. McGraw claimed the sales would not have occurred if Eli

Lilly had disclosed its risk to medical providers. He wrote, " The money paid

by the State would not have been paid to Eli Lilly except for its fraudulent

conduct. " He asked for three times the amount of the overpayments. Article

Complaint

United States

January 2004, the Office of the Inspector General for the U.S. Office of

Personnel Management asked J & J for documents related to payments made to

doctors in connection with sales, marketing and clinical trials for

Risperdal. Article

November 3, 2005 Eli Lilly reported to the Securities and Exchange

Commission that the U.S. attorney's office in Massachusetts subpoenaed the

company, seeking documents on Lilly's business relationship with an unnamed

long-term care pharmacy related to some of the company's drugs, including

the antipsychotic drug Zyprexa. Article

November 2005 J & J's Janssen unit received a subpoena from the U.S.

Attorney's Office in Philadelphia seeking information about marketing and

adverse side effects of Risperdal, according to an October 2006 regulatory

filing.Article

December 21, 2006 Bristol-Myers Squibb reported that it reached a tentative

agreement to pay $499 million to settle a federal investigation into illegal

sales and marketing activities from the late 1990s through 2005. The United

States attorney's office in Boston, which first subpoenaed the records of

Bristol-Myers in the matter in 2003, declined to confirm the announcement,

saying it did not comment on such negotiations unless a final settlement has

been signed. Jeff Macdonald, a company spokesman, confirmed previous reports

that one product involved was the antipsychotic drug Abilify. Article

March 1, 2007 Congressman Henry A. Waxman, Chairman of the Committee on

Oversight and Government, requested information relevant to Seroquel from

AstraZeneca: " Allegations have been raised that AstraZeneca inappropriately

marketed Seroquel " . Subpoena

March 1, 2007 Congressman Henry A. Waxman, Chairman of the Committee on

Oversight and Government, requested information relevant to Zyprexa from Eli

Lilly: " Allegations have been raised that Eli Lilly misled physicians and

inappropriately promoted off-label uses of Zyprexa " Subpoena

March 12, 2007 & said that it had received subpoenas from

U.S. attorneys in Philadelphia, Boston and San Francisco over allegations

the company marketed schizophrenia drug Risperdal for unapproved

uses.Article

NAMI's Role in the Scheme

Local 28 Sheet Metal Workers v. Lilly

Lilly also utilized a non-profit organization as a front to further its own

purposes of increasing market share for atypical antipsychotics. Lilly’s

funding and partnering with the National Alliance for the Mentally Ill

(NAMI) in the late 1990s and early 2000s was designed to accomplish through

a non-profit organization what it could not on its own: giving the

appearance of independent analysis and a grassroots movement encouraging the

use of atypical antipsychotics by state and private insurers. The scheme

worked and Lilly certainly benefited from its significant donations to NAMI.

Zyprexa was the leading antipsychotic in the world in 2000, capturing nearly

40% of the global antipsychotic market. A year later, Zyperexa was the sixth

highest selling pharmaceutical product in the world, with $3.2 billion in

sales. Complaint

UFCW Local 1776 v. Lilly

Lilly has been the largest contributor among pharmaceutical manufacturers to

NAMI, giving the organization approximately $2.87 million between 1996 and

1999. Lilly “donations” to NAMI were not limited to money. In 1999, Mother

Magazine reported that Lilly executive Jerry Radke was “on loan” to

NAMI as an executive. Also in 1999, Bob Postlethwait, a Lilly executive (and

TeenScreen advisor) who headed the group that produced and marketed Zyprexa

assisted NAMI Indiana in securing government funding for an executive

director. Lilly also provided funding for a variety of brochures and

programs produced by NAMI highlighting the use of atypical antipsychotics.

One such Lilly-funded brochure – “Understanding Schizophrenia” – produced by

NAMI for patients and families of schizophrenics minimized the side effects

of atypical antipsychotics such as Zyprexa. Another – the 2001 “Access to

Effective Medications” brochure produced by NAMI National for legislators

and paid for by Lilly – lays out a blueprint for nationwide NAMI lobbying of

state governments to reduce or remove any limitations to payments for

atypical antipsychotics, again down-playing the side effects of such drugs.

Using money from Lilly and other pharmaceutical companies, NAMI – both the

various state-level association and the national organization – has

effectively lobbied state and federal governments to increase spending on

atypical antipsychotic drugs and to reduce restrictions on access to those

pharmaceuticals, thereby protecting pharmaceutical industry profits through

the guise of independent, grassroots advocacy. For example, between 1998 and

2000, Lilly gave NAMI Washington State $91,000. During that time, NAMI

Washington State, in an effort led by NAMI lobbyist Brad Boswell, lobbied

the state legislature for $1 million specifically for atypical antipsychotic

drugs. Brad Boswell was Lilly’s Washington state lobbyist just prior to his

assignment with NAMI Washington State. NAMI also joined a suit initiated by

the Pharmaceutical Research and Manufacturers of America (PhRMA) against the

state of Michigan in order to increase physician access to higher cost

pharmaceuticals – including atypical antipsychotics – under the state’s

Medicaid program. Class Action Complaint